Five Prime Therapeutics (FPRX) Misses Q3 EPS by 8c

Five Prime Therapeutics (NASDAQ: FPRX) reported Q3 EPS of ($1.03), $0.08 worse than the analyst estimate of ($0.95). Revenue for the quarter came in at $2.98 million versus the consensus estimate of $5.23 million.

“We have advanced all of our wholly-owned programs according to our plan for 2019,” said William Ringo, Chairman and interim Chief Executive Officer of Five Prime Therapeutics. “As we approach 2020, we have repositioned Five Prime with a focus on prioritizing our pipeline based on upcoming data readouts, while also extending our cash runway, in order to maximize the long-term potential of the company.”

For earnings history and earnings-related data on Five Prime Therapeutics (FPRX) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Jefferies upgrades Five Below to Buy, sees path to TJX-like re-rating
• Cantor Fitzgerald Reiterates Overweight Rating on Global Net Lease (GNL)